References

  1. Viatris data on file (myl_xen_dof_v1)
  2. Xenidate XL. Summary of Product Characteristics (SPC) – all doses. Available at https://www.medicines.org.uk/emc/search?q=Xenidate+XL. Last accessed: December 2025.
  3. NICE. Methylphenidate hydrochloride. Available at: https://bnf.nice.org.uk/medicinal-forms/methylphenidate-hydrochloride.html. Last accessed: December 2025
  4. Holden SE et al. The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child and Adolescent Psychiatry and Mental Health 2013;7:34.
  5. Xenidate XL. Patient information Leaflets – all doses. Available at https://www.medicines.org.uk/emc/search?q=Xenidate+XL. Last accessed: December 2025
  6. NHS Conditions: ADHD in children and young people. Available at: https://www.nhs.uk/conditions/adhd-children-teenagers/. Last accessed: December 2025.
  7. NICE guideline 87. Attention deficit hyperactivity disorder: diagnosis and management. March 2018. Available at: www.nice.org.uk/guidance/ng87. Last Accessed: December 2025
  8. NHS England. Medicines Value And Access Function. Available at: https://www.england.nhs.uk/medicines-2/medicines-value-and-access/. Last Accessed: December 2025

UK-MET-2025-00010 October 2025